Global Oncology Biosimilars Market: Overview
This report on the oncology biosimilars market analyzes the current and future scenario of the global market. Increasing prevalence of cancer, innovation in the development of new drugs, pipeline analysis, and drug class sales during the forecast period.
The global oncology biosimilars market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country’s market with respect to the segments based on drug class, disease indication, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises key molecules, Porters Five Forces Analysis and cancer statistics to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global oncology biosimilars market.
Global Oncology Biosimilars Market: Market Segmentation
Based on drug class, the market has been segmented into three major drug class such as G-CSF, monoclonal antibody, hematopoietic agents. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
In terms of disease indication – the oncology biosimilars market has been segmented into following segments including breast cancer, non-small cell lung cancer, colorectal cancer, neutropenia, blood cancer and others. . All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.
As per distribution channels, the oncology biosimilars market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online pharmacy. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Geographically, oncology biosimilars market on the basis of region has been segmented into North America, Europe, Asia Pacific and Rest of the World. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report. The report also profiles major key players in the oncology biosimilars market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis.
Global Oncology Biosimilars Market: Competitive Dynamics
Key players for oncology biosimilars market profiled in this report are Celltrion Inc., Pfizer, Inc., Biocon, Sandoz International GmbH (A Novartis Division), Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Apotex Inc. (Apobiologix), Intas Pharmaceuticals Ltd. And BIOCAD.
The Oncology Biosimilars Market has been segmented as follows:
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote